Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC
Kaiwen Wang(The University of Texas MD Anderson Cancer Center), Xiuning Le(The University of Texas MD Anderson Cancer Center), Robyn Du(The University of Texas MD Anderson Cancer Center), Marcelo V. Negrão(The University of Texas MD Anderson Cancer Center), Lingzhi Hong(The University of Texas MD Anderson Cancer Center), Waree Rinsurongkawong(The University of Texas MD Anderson Cancer Center), Keunchil Park(The University of Texas MD Anderson Cancer Center), Heather A. Wakelee(Palo Alto Institute), David R. Gandara(University of California, Davis), John V. Heymach(The University of Texas MD Anderson Cancer Center), Ferdinandos Skoulidis(The University of Texas MD Anderson Cancer Center), Ara A. Vaporciyan(The University of Texas MD Anderson Cancer Center), Janet Tu(The University of Texas MD Anderson Cancer Center), Anne S. Tsao(The University of Texas MD Anderson Cancer Center), Christina S. Baik(Seattle Cancer Care Alliance), Whitney E. Lewis(The University of Texas MD Anderson Cancer Center), Tina Cascone(The University of Texas MD Anderson Cancer Center), Lauren A. Byers(The University of Texas MD Anderson Cancer Center), Catherine A. Shu(Columbia University Irving Medical Center), Deepti Behl(Sutter Medical Center), Jonathan W. Riess(University of California Davis Medical Center), Jianjun Zhang(The University of Texas MD Anderson Cancer Center), Nathaniel J. Myall(Stanford University), J.V. Pozadzides(The University of Texas MD Anderson Cancer Center), Natalie Uy(University of Washington), Don L. Gibbons(The University of Texas MD Anderson Cancer Center)
Cited by 26
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k